EA2201: An ECOG-ACRIN phase II study of neoadjuvant nivolumab plus ipilimumab and short course radiation in MSI-H/dMMR rectal tumors. Background: The prognostic advantage of early stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results